1. Anavex Withdraws EU Marketing Bid for Alzheimer's Drug, Stock Plummets
Anavex Life Sciences Corp. has abruptly withdrawn its marketing authorization application (MAA) for its lead Alzheimer's disease therapy, blavatide, from the European Medicines Agency (EMA). The immediate market reaction was severe, with the company's stock price dropping sharply following the announcement. This sudden...